Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT-COVID: Heterologous COVID-19 Vaccine Combinations in Pakistan
NCT05162482Phase 2Unknown
- Sponsor
- Aga Khan University Hospital
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Viral Vector Vaccines, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BBIBP-CorV, ad5-ncov and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by Aga Khan University Hospital. Primary endpoint: Anti-spike IgG antibodies at Week 38. Status: unknown.
02
Drugs
BBIBP-CorVad5-ncovChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05162482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162482.